Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS

V. Tomassini, L. De Giglio, M. Reindl, P. Russo, I. Pestalozza, P. Pantano, T. Berger, Carlo Pozzilli

Research output: Contribution to journalArticle

Abstract

The aim of this study was to test the contribution of anti-myelin antibodies in predicting conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) when considering either Poser's or McDonald's diagnostic criteria. Fifty-one patients with CIS and abnormal brain MRI were imaged monthly for six months and then at 12, 18, 24, 36 months. At baseline serum samples testing antibodies against myelin oligodendrocyte glycoprotein (anti-MOG) and myelin basic protein (anti-MBP) were collected. During the 36-month follow-up, 26 (51%) patients developed a relapse thus becoming clinically definite MS (CDMS) according to Poser's criteria; 46 (90.2%) patients converted to MS according to McDonald's criteria. Out of 51 patients, 28 (54.9%) had either double or single positivity for anti-myelin antibodies. Antibody status significantly predicted MS according to Poser's criteria (P=0.004), but did not according to the McDonald's criteria. When compared to antibody negative patients, the risk of developing a relapse was 8.9 (95% Cl: 2.7-29.8; P

Original languageEnglish
Pages (from-to)1086-1094
Number of pages9
JournalMultiple Sclerosis Journal
Volume13
Issue number9
DOIs
Publication statusPublished - Nov 2007

Fingerprint

Myelin Sheath
Multiple Sclerosis
Anti-Idiotypic Antibodies
Antibodies
Myelin-Oligodendrocyte Glycoprotein
Recurrence
Myelin Basic Protein
Brain
Serum

Keywords

  • Clinically isolated syndrome
  • MBP antibodies
  • MOG antibodies
  • MRI
  • Multiple sclerosis
  • Relapse

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Tomassini, V., De Giglio, L., Reindl, M., Russo, P., Pestalozza, I., Pantano, P., ... Pozzilli, C. (2007). Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Multiple Sclerosis Journal, 13(9), 1086-1094. https://doi.org/10.1177/1352458507077622

Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. / Tomassini, V.; De Giglio, L.; Reindl, M.; Russo, P.; Pestalozza, I.; Pantano, P.; Berger, T.; Pozzilli, Carlo.

In: Multiple Sclerosis Journal, Vol. 13, No. 9, 11.2007, p. 1086-1094.

Research output: Contribution to journalArticle

Tomassini, V, De Giglio, L, Reindl, M, Russo, P, Pestalozza, I, Pantano, P, Berger, T & Pozzilli, C 2007, 'Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS', Multiple Sclerosis Journal, vol. 13, no. 9, pp. 1086-1094. https://doi.org/10.1177/1352458507077622
Tomassini, V. ; De Giglio, L. ; Reindl, M. ; Russo, P. ; Pestalozza, I. ; Pantano, P. ; Berger, T. ; Pozzilli, Carlo. / Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. In: Multiple Sclerosis Journal. 2007 ; Vol. 13, No. 9. pp. 1086-1094.
@article{d8fe3649c518418cbba61b52c01fc9d6,
title = "Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS",
abstract = "The aim of this study was to test the contribution of anti-myelin antibodies in predicting conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) when considering either Poser's or McDonald's diagnostic criteria. Fifty-one patients with CIS and abnormal brain MRI were imaged monthly for six months and then at 12, 18, 24, 36 months. At baseline serum samples testing antibodies against myelin oligodendrocyte glycoprotein (anti-MOG) and myelin basic protein (anti-MBP) were collected. During the 36-month follow-up, 26 (51{\%}) patients developed a relapse thus becoming clinically definite MS (CDMS) according to Poser's criteria; 46 (90.2{\%}) patients converted to MS according to McDonald's criteria. Out of 51 patients, 28 (54.9{\%}) had either double or single positivity for anti-myelin antibodies. Antibody status significantly predicted MS according to Poser's criteria (P=0.004), but did not according to the McDonald's criteria. When compared to antibody negative patients, the risk of developing a relapse was 8.9 (95{\%} Cl: 2.7-29.8; P",
keywords = "Clinically isolated syndrome, MBP antibodies, MOG antibodies, MRI, Multiple sclerosis, Relapse",
author = "V. Tomassini and {De Giglio}, L. and M. Reindl and P. Russo and I. Pestalozza and P. Pantano and T. Berger and Carlo Pozzilli",
year = "2007",
month = "11",
doi = "10.1177/1352458507077622",
language = "English",
volume = "13",
pages = "1086--1094",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "9",

}

TY - JOUR

T1 - Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS

AU - Tomassini, V.

AU - De Giglio, L.

AU - Reindl, M.

AU - Russo, P.

AU - Pestalozza, I.

AU - Pantano, P.

AU - Berger, T.

AU - Pozzilli, Carlo

PY - 2007/11

Y1 - 2007/11

N2 - The aim of this study was to test the contribution of anti-myelin antibodies in predicting conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) when considering either Poser's or McDonald's diagnostic criteria. Fifty-one patients with CIS and abnormal brain MRI were imaged monthly for six months and then at 12, 18, 24, 36 months. At baseline serum samples testing antibodies against myelin oligodendrocyte glycoprotein (anti-MOG) and myelin basic protein (anti-MBP) were collected. During the 36-month follow-up, 26 (51%) patients developed a relapse thus becoming clinically definite MS (CDMS) according to Poser's criteria; 46 (90.2%) patients converted to MS according to McDonald's criteria. Out of 51 patients, 28 (54.9%) had either double or single positivity for anti-myelin antibodies. Antibody status significantly predicted MS according to Poser's criteria (P=0.004), but did not according to the McDonald's criteria. When compared to antibody negative patients, the risk of developing a relapse was 8.9 (95% Cl: 2.7-29.8; P

AB - The aim of this study was to test the contribution of anti-myelin antibodies in predicting conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) when considering either Poser's or McDonald's diagnostic criteria. Fifty-one patients with CIS and abnormal brain MRI were imaged monthly for six months and then at 12, 18, 24, 36 months. At baseline serum samples testing antibodies against myelin oligodendrocyte glycoprotein (anti-MOG) and myelin basic protein (anti-MBP) were collected. During the 36-month follow-up, 26 (51%) patients developed a relapse thus becoming clinically definite MS (CDMS) according to Poser's criteria; 46 (90.2%) patients converted to MS according to McDonald's criteria. Out of 51 patients, 28 (54.9%) had either double or single positivity for anti-myelin antibodies. Antibody status significantly predicted MS according to Poser's criteria (P=0.004), but did not according to the McDonald's criteria. When compared to antibody negative patients, the risk of developing a relapse was 8.9 (95% Cl: 2.7-29.8; P

KW - Clinically isolated syndrome

KW - MBP antibodies

KW - MOG antibodies

KW - MRI

KW - Multiple sclerosis

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=39549088973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39549088973&partnerID=8YFLogxK

U2 - 10.1177/1352458507077622

DO - 10.1177/1352458507077622

M3 - Article

C2 - 17468447

AN - SCOPUS:39549088973

VL - 13

SP - 1086

EP - 1094

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 9

ER -